Sign Up Today and Learn More About IMPACT Therapeutics Stock
Invest in or calculate the value of your shares in IMPACT Therapeutics or other pre-IPO companies through EquityZen's platform.
IMPACT Therapeutics Stock (IMTT)
IMPACT Therapeutics is a therapeutics company dedicated to the development of similar drugs to treat cancer.
About IMPACT Therapeutics Stock
Founded
2009
Industries
Science and Engineering, Health Care, Biotechnology
IMPACT Therapeutics Press Mentions
Stay in the know about the latest news on IMPACT Therapeutics
Innovative Treatments Boost Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market to $13.45 billion By 2029
einpresswire • May 17, 2025
Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof
patents • May 04, 2025
PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORMULATION, METHOD FOR PREPARING AN …
patents • May 04, 2025
Hedgehog Pathway Inhibitors Market Report 2025: Analysis and Forecast (2020-2030) by Generic Drug, Dosage, End User, Region and Company - Featuring BridgeBio Pharma, Eli Lilly, Roche & More
globenewswire • Apr 26, 2025
Impact Therapeutics divulges new PARP-1 inhibitors
bioworld • Apr 10, 2025
IMPACT Therapeutics Management
Leadership team at IMPACT Therapeutics
CEO&CSO
Edward Tian
President & CEO
Jun Bao
Join now and verify your accreditation status to gain access to:
- IMPACT Therapeutics Current Valuation
- IMPACT Therapeutics Stock Price
- IMPACT Therapeutics Management
- Available deals in IMPACT Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- IMPACT Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- IMPACT Therapeutics Revenue and Financials
- IMPACT Therapeutics Highlights
- IMPACT Therapeutics Business Model
- IMPACT Therapeutics Risk Factors
- IMPACT Therapeutics Research Report from SACRA Research
Trading IMPACT Therapeutics Stock
How to invest in IMPACT Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like IMPACT Therapeutics through EquityZen funds. These investments are made available by existing IMPACT Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell IMPACT Therapeutics stock?
Shareholders can sell their IMPACT Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
